Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company Halozyme Therapeutics has dosed its first patient in a clinical trial evaluating subcutaneous administration of morphine with its spreading agent Hylenex.
Subscribe to our email newsletter
Hylenex is a liquid injectable formulation that includes the active pharmaceutical ingredient, recombinant human hyaluronidase (rHuPH20). Morphine is a widely used drug for pain management and is currently approved for both intravenous and subcutaneous administration.
More rapid absorption facilitated by Hylenex via the subcutaneous (SC) route of administration could shorten the time of onset for achieving effective pain relief for patients, without the burden of intravenous (IV) administration.
Halozyme’s product is approved for use as a spreading agent to accelerate the delivery of fluids and drugs, such as local anesthesics, contrast agents, and for subcutaneous fluid replacement.
The morphine study is designed to determine the time to maximal blood levels of morphine after subcutaneous administration with and without Hylenex, and to assess safety and tolerability. The placebo-controlled crossover study will enroll up to 18 subjects.